Abstract
Premenstrual tension or, more commonly premenstrual syndrome (PMS), is a long-recognized heterogeneous symptom complex that has defied adequate characterization, elucidation of pathophysiology, and treatment for many years. First described by Frank1 in 1931, premenstrual syndrome has taken on a spectrum of presentations ranging from purely physiologic symptoms during the luteal phase (molimina) to a pattern of aberrant violent behavior that has apparently involved assault, child abuse, spouse battering, and murder.2 The myriad of reported symptoms attributed to the premenstrual interval is pointless to list, but those most likely to be associated with endocrine changes in the premenstruum are noted in Table 22–1. In general, they most often involve breast symptoms, fluid retention, and emotional changes. The pattern of waxing and waning symptoms, which typically encompass approximately the last 7 days of a luteal phase, is actually highly variable. It presents with a spectrum of symptoms starting from the periovulatory interval to only 1 or 2 days premenstrually, and with resolution occurring from initiation of menses to the end of the menstrual flow.3 Thus, defining what “PMS” really means is not always clear cut. Documentation of cyclic symptomatology in relationship to the menses may require charting of symptoms on a menstrual calendar to determine whether such an association really exists. However, the problem of self-evaluation has been demonstrated by a study in which women reported “premenstrual” symptoms when they were falsely told their cycles would be shortened by medication, but menses did not actually occur until the expected time.4 Generally, follicular phase symptoms or intermittent acyclic symptoms are unlikely to be due to endocrine changes related to the menstrual cycle. This is further compounded by the presence of apparent premenstrual symptoms in some women without evidence of ovulation as well as some receiving anovulatory steroids. The opposite effect may be obtained, on the other hand, where unexplained cyclic symptomatology is found to relate to the menstrual cycle when previously unexplained.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Frank RT: The hormonal causes of premenstrual tension. Arch Neurol Psychiatry 26: 1053, 1931
Dalton K: Cyclical criminal acts in premenstrual syndrome. Lancet 2: 1070, 1980
Reid RL, Yen SSC: The premenstrual syndrome. Clin Obstet Gynecol 26: 710, 1983
Ruble DN: Premenstrual symptoms; a reinterpretation. Science 197: 291, 1977
Greene R, Dalton K: The premenstrual syndrome. Br Med J 1: 1007, 1953
Reid RL, Yen SSC: Premenstrual syndrome. Am J Obstet Gynecol 139: 85, 1981
Dalton K: The Premenstrual Syndrome and Progesterone Therapy. London, Heinemann, 1977
Morton JH: Premenstrual tension. Am J Obstet Gynecol 60: 343, 1950
Backstrom T, Carstensen H: Estrogen and progesterone in plasma in relation to premenstrual tension. J Steroid Biochem 5: 257, 1974
Backstrom T, Mattsson B: Correlation of symptoms in premenstrual tension to oestrogen and progesterone concentrations in blood plasma. Neuropsychobiology 1: 80, 1975
Munday M: Hormone levels in severe premenstrual tension. CurrMedRes Opin 4: 16, 1977
Munday MR, Brush MG, Taylor RW: Correlations between progesterone, oestradiol and aldosterone levels in the premenstrual syndrome. Clin Endocr (Oxf) 14: 1, 1981
Herzberg B, Coppen A: Changes in psychological symptoms in women taking oral contraceptives. Br J Psychiatry 116: 161, 1970
Greenblatt RB: Syndrome of major menstrual molimina with hypermenorrhea alleviated by testosterone propionate. JAMA 115: 120, 1940
Gray LA: The use of progesterone in nervous tension states. South Med J 34: 1004, 1941
Bickers N, Wood M: Premenstrual tension—Rational treatment. Tex Rep Biol Med 9: 406, 1951
Loraine JA, Bell ET: Ovarian steroids, in Hormone Assays and their Clinical Application. Baltimore, Williams & Wilkins, 1971, pp 408–409
Andersch B, Hahn L, Wendestam C, et al: Treatment of premenstrual tension syndrome with bromocryptine. Acta Endocrinol 216 (Suppl 88): 165, 1978
Kutner SJ, Brown WL: Types of oral contraceptives, depression and premenstrual symptoms. J Nerv Ment Dis 155: 153, 1972
O’Brien PMS, Selby C, Symonds EM; Progesterone, fluid and electrolytes in premenstrual syndrome. Br Med J 280: 1161, 1980
Smith SL: Mood and the menstrual cycle, in Sachar B (ed): Topics in Psychoendocrinology. New York, Grune & Stratton, 1975, pp 19–58
Sampson GA: Premenstrual syndrome; a double-blind controlled trial of progesterone and placebo. Br J Psychiatry 130: 265, 1979
Parker AS: The premenstrual tension syndrome. Med Clin North Am 44: 339, 1960
Somerville BW: The role of progesterone in menstrual migraine. Neurology (NY) 21: 853, 1971
Simmons RJ: Premenstrual tension. Obstet Gynecol 8: 99, 1956
Ylostalo P, Kauppila A, Puolakka J, et al: Bromocriptine and norethisterone in the treatment of premenstrual syndrome. Obstet Gynecol 59: 292, 1982
Moos RH: Psychological aspects of oral contraceptives. Arch Gen Psychiatry 19: 87, 1968
Herzberg BN, Johnson AL, Brown S: Depressive symptoms and oral contraceptives. Br Med J 4: 142, 1970
Nilson L, Solvell L: Clinical studies on oral contraceptives—A randomized double blind crossover study of four different preparations. Acta Obstet Gynecol Scand46(Suppl 8 ): 1, 1962
Andersch B, Hahn L: Premenstrual complaints. II. Influence of oral contraceptives. Acta Obstet Gynecol Scand 60: 579, 1981
Cullberg J: Mood changes and menstrual symptoms with different estrogen combinations. Acta Psychiatr Scand (Suppl) 236: 1, 1972
Goldzieher JW, Moses LE, Averkin E, et al: Nervousness and depression attributed to oral contraceptives: A double-blind, placebo-controlled study. Am J Obstet Gynecol 111: 1013, 1971
Skinner SL, Lumbers ER, Symonds EM: Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. J Clin Sci 36: 67, 1969
Vander AJ, Geelhoed GW: Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 120: 399, 1965
Katz FH, Kappas A: The effects of estradiol and estriol on plasma levels of Cortisol and thyroid hormone-binding globulins and on aldosterone and Cortisol secretion rates in man. J Clin Invest 46: 1768, 1967
Layne DS, Meyer CJ, Vaishwaner PS, et al: The secretion and metabolism of Cortisol and aldosterone in normal and in steroid-treated women. J Clin Endocrinol Metab 22: 107, 1962
Hodge RL, Lowe RC, Vane JR: The effects of alteration of blood volume on the concentration of circulating angiotensin in anaethetized dogs. J Physiol (Lond) 186: 613, 1966
Landau RL, Lugibihl K: Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrinol Metab 18: 1237, 1958
Johnson JA, Davis JO, Baumber JS, et al: Effects of estrogens and progesterone on electrolyte balances in normal dogs. Am J Physiol 219: 1691, 1970
Thorn GW, Engel IL: The effect of sex hormones on the renal excretion of electrolytes. J Exp Med 68: 299, 1938
Sundsfjord JA, Aakvaag A: Plasma renin activity, plasma renin substrate and urinary aldosterone excretion in the menstrual cycle in relation to the concentration of progesterone and oestrogens in the plasma. Acta Endocrinol (Copenh) 71: 519, 1972
Brown JJ, Davies DL, Lever AF, et al: Variations in plasma renin during the menstrual cycle. Br Med J 2: 1114, 1964
Oelkers W, Schoneshofer M, Blumel A: Effects of progesterone and four synthetic progestogens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 39: 882, 1974
Kaulhausen H, Leyendecker G, Beuker A, et al: The relationship of the renin-angiotensin II and aldosterone excretion during the menstrual cycle. Acta Endocrinol (Copenh) 64: 152, 1970
Perrini A, Piliego N: The increases of aldosterone in the premenstrual syndrome. Minerva Med 50: 2897, 1959
Chiorboli E, Miller dePaiva L: Excretion of aldosterone in premenstrual tension. Arq Bras Endocrinol Metab 15: 107, 1966
Parker CR, Winkel CA, Rush AJ, et al: Plasma concentrations of 11-deoxycorticosterone in women during the menstrual cycle. Obstet Gynecol 58: 26, 1981
Ernest EM: Preliminary clinical report on trichlor- methiazide in premenstrual tension. Curr Ther Res 3: 221, 1961
Jungck EC, Barield WE, Greenblatt RB: Chlorothiazide and premenstrual tension. JAMA 169: 96, 1952
Baden WF, Lizcano HR: Evaluation of a new diuretic drug (Quinethazone) in the premenstrual tension syndrome. J New Drugs 3: 167, 1964
Mattson B, van Schoultz B: A comparison between lithium, placebo and a diuretic in premenstrual tension. Acta Psychiatr Scand (Suppl) 255: 74, 1974
Reeves BD, Garvin JE, McElin TW: Premenstrual tension: Symptoms and weight changes related to potassium therapy. Am J Obstet Gynecol 109: 1036, 1971
Coppen AJ, Milne HB, Outram DH, et al: Dytide, nor- ethisterone and placebo in the premenstrual syndrome. Clin Trial J 6: 33, 1969
Werch A, Kane RE: Treatment of premenstrual tension with metolazone: A double-blind evaluation of a new diuretic. Curr Ther Res 19: 565, 1976
O’Brien PMS, Craven D, Selby C, et al: Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 86: 142, 1979
Steelman SL, Brooks JB, Morgan EP, et al: Anti-an- drogenic activity of spironolactone. Steroids 14: 449, 1969
Hays RM: Antidiuretic hormone. N Engl J Med 295: 659, 1976
Bergland RM, Page RB: Pituitary-brain vascular relations: A new paradigm. Science 204: 18, 1979
Costovsky R, Wajchenberg BI, Nogneira O: Hyperresponsiveness to lysine-vasopressin in Cushing’s disease. Acta Endocrinol (Copenh) 75: 125, 1974
Zimmerman EA, Carmel PW, Husain MK, et al: Vasopressin and neurophysin: High concentrations in monkey hypophyseal portal blood. Science 182: 925, 1973
Franchimont P, Dourey C, Legros JJ, et al: Prolactin levels during the menstrual cycle. Clin Endocrinol (Oxf) 5: 643, 1976
Vekeman M, Delvoye P, L’Hermite M, et al: Serum prolactin levels during the menstrual cycle. J Clin Endocrinol Metab 44: 989, 1977
Williams RF, Barber DL, Cowan BD, et al: Hyperprolactinemia in monkeys: Induction by an estrogen-progesterone synergy. Steroids 38: 321, 1981
Halbreich U, Ben-David M, Assael M, et al: Serum-prolactin in women with premenstrual syndrome. Lancet 2: 654, 1976
Cole EN, Everend D, Horrobin DF, et al: Is prolactin a fluid and electrolyte regulating hormone in man 1J Physiol (Lond) 25: 54p, 1975
Benedek-Jaszmann LJ, Hearn-Sturtevant MD: Premenstrual tension and functional infertility. Lancet 1: 1095, 1976
Andersch B, Abrahamsson L, Wendestam C, et al: Hormone profile in premenstrual tension: Effects of bromocriptine and diuretics. Clin Endocrinol (Oxf) 11: 657, 1979
Andersen AN, Larsen JF, Steenstrup OR, et al: Effect of bromocryptine on the premenstrual syndrome: A double blind clinical trial. Br J Obstet Gynaecol 84: 370, 1977
Graham J J, Harding PE, Wise PH, et al: Prolactin suppression in the treatment of premenstrual syndrome, Med J Aust (Suppl) 2: 18, 1978
Ghose K, Coppen A: Bromocryptine and premenstrual syndrome: Controlled study. Br Med J 1: 147, 1977
Andersen AN, Larsen JF: Bromocriptine in the treatment of premenstrual syndrome. Drugs 17: 383, 1979
Mansel RE, Preece PE, Hughes LE: A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 65: 724, 1978
Fitzsimmons JT, Setler PE: The relative importance of central nervous catecholaminergic and cholinergic mechanisms in drinking in response to angiotensin and other thirst stimuli. J Physiol (Lond) 250: 613, 1975
Kuchel O, Buu NT, Unger T: Dopamine-sodium relationship. Is dopamine a part of the endogenous natriuretic system? Contrib Nephrol 13: 27, 1978
Kullander S, Svanberg L: Bromocriptine treatment of the premenstrual syndrome. Acta Obstet Gynecol Scand 58: 375, 1979
Eisner CW, Buster JE, Schindler RA, et al: Bromocriptine in the treatment of premenstrual tension syndrome. Obstet Gynecol 56: 723, 1980
Rose DP: The interactions between vitamin B6 and hormones. VitamHorm 36: 53, 1978
Delitala G, Masala A, Alagna S, et al: Effect of pyridoxine on human hypophyseal trophic hormone release: A possible stimulation of hypothalamic dopaminergic pathway. J Clin Endocrinol Metab 42: 603, 1976
Mcintosh EN: Treatment of women with galactorrhea-amenorrhea syndrome with pyridoxine (vitamin B6). J Clin Endocrinol Metab 42: 1192, 1976
DeWaal JM, Steyn AF, Harms JHK, et al: Failure of pyridoxine to suppress raised serum prolactin levels. SAfr Med J 53: 293, 1978
Husami N, Idriss W, Jewelewicz R, et al: Lack of acute effects of pyridoxine on prolactin secretion and lactation. Fertil Steril 30: 393, 1978
Lehtovirta P, RantaT, Seppala M: Pyridoxine treatment of galactorrhea-amenorrhea syndromes. Acta Endocrinol (Copenh) 87: 682, 1978
Abraham GE, Hargrove JT: Effect of vitamin B6 on premenstrual symptomatology in women with tension syndrome; a double blind crossover study. Infertility 3:155, 1980
Morton JH, Addison H, Addison RG, et al: A clinical study of premenstrual tension. Am J Obstet Gynecol 65: 1182, 1953
DePirro R, Fusco A, Bertoli A, et al: Insulin receptors during the menstrual cycle in normal women. J Clin Endocrinol Metab 47: 1387, 1978
Heckel GP: Endogenous allergy to steroid hormones. Surg Gynecol Obstet 92: 191, 1951
Kuchel O, Cuche JI, Buu NT, et al: Catcholamine excretion in “idiopathic” edema: decreased dopamine excretion. A pathogenic factor. J Clin Endocrinol Metab 44: 639, 1977
Briggs M, Briggs M: Relationship between monoamine oxidase activity and sex hormone concentration in human blood plasma. J Reprod Fertil 29: 447, 1972
Quigley ME, Yen SSC: The role of endogenous opiates on LH secretion during the menstrual cycle. J Clin Endocrinol Metab 51: 179, 1980
Ropert JF, Quigley ME, Yen SSC: Endogenous opiates modulate pulsatile luteinizing hormone release in humans. J Clin Endocrinol Metab 52: 583, 1981
Wardlaw SL, Wehrenberg WB, Ferin M, et al: Effect of sex steroids on β-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 55: 877, 1982
Reid RL, Hoff JD, Yen SSC, et al: Effects of exogenous β-endorphin on pituitary secretion and its disappearance rate in normal human subjects. J Clin Endocrinol Metab 52: 1179, 1981
Weitzman RE, Fisher DA, Minick S, et al: β-endorphin stimulates secretion of vasopressin in vivo. Endocrinology 101: 1643, 1977
Lightman SI, Forsling ML: Evidence for endogenous opioid control of vasopressin release in man. J Clin Endocrinol Metab 50: 569, 1980
Reid RL, Yen SSC: β-Endorphin stimulates the secretion of insulin and glucagon in humans. J Clin Endocrinol Metab 52: 592, 1981
Wehrenberg WB, Wardlaw SI, Frantz AG, et al: β-endorphin in hypophyseal-portal blood: Variations throughout the menstrual cycle. Endocrinology 111: 879, 1982
Cohen MR, Cohen RM, Pickar D, et al: Behavioral effects after high dose naloxone administration to normal volunteers. Lancet 2: 1110, 1981
Collier HOJ, Roy AC: Morphine-like drugs inhibit the stimulation by E prostaglandins of cyclic AMP formation by rat brain homogenates. Nature (Lond) 248: 24, 1974
Dawood MY: Dysmenorrhea. Clin Obstet Gynecol 26: 719, 1983
Budoff PW: Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. N Engl J Med 307: 714, 1982
Wood C, Jakubowicz D: The treatment of premenstrual symptoms with mefenamic acid. Br J Obstet Gynecol 87: 627, 1980
Abraham GE, Lubran MM: Serum and red cell magnesium levels in patients with premenstrual tension, Am J Clin Nutr 34: 2364, 1981
O’Brien PM: The premenstrual syndrome: A review of the present status of therapy. Drugs 24: 140, 1982
Day J: Danazol and the premenstrual syndrome. Postgrad Med 7 55: 87, 1979
Barbieri RL, Evans S, Kistner RW: Danazol in the treatment of endometriosis: Analysis of 100 cases with a 4-year follow up. Fertil Steril 37: 737, 1982
Meldrum DR, Chang RJ, Liu J, et al: “Medical oophorectomy” using a long-acting GnRH agonist—A possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 54: 1081, 1982
Streeten DH: Idiopathic edema: Pathogenesis, clinical features, and treatment. Metabolism 27: 353, 1978
Edwards CRW, Besser G, Thorner MD: Bromocryptine- responsive form of idiopathic edema. Lancet 2: 94, 1979
Ferris TF, Chonko AM, Williams JS, et al: Studies of the mechanism of sodium retention in idiopathic edema. Trans Assoc Am Physicians 86: 310, 1973
Norbiato G, Bevilacqua M, Raggi U, et al: Effect of metoclopramide, a dopaminergic inhibitor, on renin and aldosterone in idiopathic edema: Possible therapeutic approach with levodopa and carbidopa. J Clin Endocrinol Metab 48: 37, 1979
Sowers JR, Beck FW, Berg G: Altered dopaminergic modulation of 18-hydroxycorticosterone secretion in idiopathic edema: Therapeutic effects of bromocriptine. J Clin Endocrinol Metab 55: 749, 1982
Thibonnier M, Marchetti J, Corvol P, et al: Abnormal regulation of antidiuretic hormone in idiopathic edema. Am J Med 67: 67, 1979
Sowers J, Catania R, Paris J, et al: Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: Possible therapeutic approach. J Clin Endocrinol Metab 54: 510, 1982
MacGregor GA, Markandu ND, Roulston JE, et al: Is idiopathic edema idiopathic? Lancet 1: 397, 1979
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Publishing Corporation
About this chapter
Cite this chapter
Marut, E.L. (1987). Premenstrual Tension and Idiopathic Edema. In: Gold, J.J., Josimovich, J.B. (eds) Gynecologic Endocrinology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2157-6_22
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2157-6_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9272-2
Online ISBN: 978-1-4613-2157-6
eBook Packages: Springer Book Archive